Income Statement Exact Sciences Corporation
Equities
EXAS
US30063P1057
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.91 USD | -2.64% |
|
-2.72% | -7.62% |
Jul. 09 | Tariff Drama, Minimal Market Reaction | ![]() |
Jul. 09 | Exact Sciences Says Its Oncodetect Test to Detect Colorectal Cancer Gets Medicare Coverage | MT |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.49B | 1.77B | 2.08B | 2.5B | 2.76B | |||||
Total Revenues | 1.49B | 1.77B | 2.08B | 2.5B | 2.76B | |||||
Cost of Goods Sold, Total | 354M | 459M | 574M | 654M | 840M | |||||
Gross Profit | 1.14B | 1.31B | 1.51B | 1.85B | 1.92B | |||||
Selling General & Admin Expenses, Total | 1.07B | 1.52B | 1.64B | 1.64B | 1.68B | |||||
R&D Expenses | 554M | 386M | 393M | 426M | 431M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 93.4M | 95M | 97.45M | 92.16M | - | |||||
Other Operating Expenses | - | - | - | -2.03M | - | |||||
Other Operating Expenses, Total | 1.72B | 2B | 2.13B | 2.15B | 2.11B | |||||
Operating Income | -582M | -689M | -621M | -309M | -192M | |||||
Interest Expense, Total | -95.98M | -18.61M | -19.63M | -19.45M | -27.02M | |||||
Interest And Investment Income | 6.9M | 31.78M | - | 32.71M | 39.56M | |||||
Net Interest Expenses | -89.09M | 13.17M | -19.63M | 13.27M | 12.54M | |||||
EBT, Excl. Unusual Items | -671M | -675M | -641M | -296M | -179M | |||||
Merger & Related Restructuring Charges | - | -141M | - | - | - | |||||
Gain (Loss) On Sale Of Investments | - | - | -19.42M | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | -13.24M | - | - | |||||
Asset Writedown | -210M | -20.21M | -15.97M | -621K | -869M | |||||
Other Unusual Items | 23.66M | -6.36M | 56.62M | 94.44M | 12.54M | |||||
EBT, Incl. Unusual Items | -857M | -843M | -633M | -202M | -1.04B | |||||
Income Tax Expense | -8.57M | -247M | -9.06M | 2.4M | -7.3M | |||||
Earnings From Continuing Operations | -849M | -596M | -624M | -204M | -1.03B | |||||
Net Income to Company | -849M | -596M | -624M | -204M | -1.03B | |||||
Net Income - (IS) | -849M | -596M | -624M | -204M | -1.03B | |||||
Net Income to Common Incl Extra Items | -849M | -596M | -624M | -204M | -1.03B | |||||
Net Income to Common Excl. Extra Items | -849M | -596M | -624M | -204M | -1.03B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -5.61 | -3.48 | -3.54 | -1.13 | -5.59 | |||||
Basic EPS - Continuing Operations | -5.61 | -3.48 | -3.54 | -1.13 | -5.59 | |||||
Basic Weighted Average Shares Outstanding | 151M | 171M | 176M | 180M | 184M | |||||
Net EPS - Diluted | -5.61 | -3.48 | -3.54 | -1.13 | -5.59 | |||||
Diluted EPS - Continuing Operations | -5.61 | -3.48 | -3.54 | -1.13 | -5.59 | |||||
Diluted Weighted Average Shares Outstanding | 151M | 171M | 176M | 180M | 184M | |||||
Normalized Basic EPS | -2.78 | -2.46 | -2.27 | -1.03 | -0.61 | |||||
Normalized Diluted EPS | -2.78 | -2.46 | -2.27 | -1.03 | -0.61 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | -419M | -508M | -423M | -102M | 23.07M | |||||
EBITA | -489M | -594M | -523M | -217M | -96.63M | |||||
EBIT | -582M | -689M | -621M | -309M | -192M | |||||
EBITDAR | -393M | -471M | -379M | -56.45M | 64.96M | |||||
Total Revenues (As Reported) | - | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | 1 | 29.3 | 1.43 | -1.19 | 0.7 | |||||
Current Domestic Taxes | 799K | 1.39M | 2.17M | 2.27M | 933K | |||||
Current Foreign Taxes | 933K | 4.9M | 1.13M | 2.56M | 1.88M | |||||
Total Current Taxes | 1.73M | 6.29M | 3.3M | 4.83M | 2.82M | |||||
Deferred Domestic Taxes | -10.42M | -253M | -12.22M | 566K | -9.92M | |||||
Deferred Foreign Taxes | 120K | 54K | -147K | -2.99M | -199K | |||||
Total Deferred Taxes | -10.3M | -253M | -12.36M | -2.42M | -10.12M | |||||
Normalized Net Income | -419M | -422M | -400M | -185M | -112M | |||||
Interest on Long-Term Debt | 87.19M | 17.16M | 16.95M | 24.33M | 33.97M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 93.2M | 144M | 170M | 138M | 180M | |||||
Marketing Expenses | 134M | 194M | 238M | 184M | 213M | |||||
Selling and Marketing Expenses | 590M | 862M | 846M | 727M | 894M | |||||
General and Administrative Expenses | 482M | 654M | 794M | 911M | 785M | |||||
Research And Development Expense From Footnotes | 846M | 470M | 393M | 426M | 431M | |||||
Net Rental Expense, Total | 25.61M | 37.57M | 44.75M | 45.78M | 41.89M | |||||
Imputed Operating Lease Interest Expense | 14.53M | 2.35M | 2.89M | 2.83M | 3.39M | |||||
Imputed Operating Lease Depreciation | 11.08M | 35.22M | 41.86M | 42.94M | 38.5M | |||||
Stock-Based Comp., COGS (Total) | - | - | 19.22M | 20.76M | 20.52M | |||||
Stock-Based Comp., R&D Exp. (Total) | - | - | 33.82M | 41.24M | 39.68M | |||||
Stock-Based Comp., S&M Exp. (Total) | - | - | 62.57M | 65.55M | 68.24M | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | 91.21M | 104M | 86.45M | |||||
Stock-Based Comp., Other (Total) | 153M | 253M | - | - | - | |||||
Total Stock-Based Compensation | 153M | 253M | 207M | 231M | 215M |
- Stock Market
- Equities
- EXAS Stock
- Financials Exact Sciences Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions